Bart Neyns | Charles Explorer

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis

2017 | Publikace bez příslušnosti k fakultě